Home

human lives
drive our discovery
of microbiome therapeutics

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more

Pipeline

We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.

Learn more

Featured news

Finch Therapeutics Presents Data from its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences

October 28, 2020

Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs

Sep 17, 2020

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

Jun 19, 2020

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more